Diasorin S.p.a. · MIL:DIA
Diasorin — Investor Day (2026)
12 slides from Diasorin's investor day presentation, Sep 30, 2026
Slide 1: Strategic Overview
02 STRATEGIC OVERVIEW Carlo Rosa
Slide 2: We have achieved significant progress since our last Investor Day
02 | STRATEGIC OVERVIEW Specialist positioning | Diasorin uniqueness We have achieved significant progress since our last Investor Day TODAY U.S. accounts for Expanded our presence in the U.S. market ~50% of our 40% of global IVD market Total Revenue Molecular is our Gained access to a unique multip
Slide 3: IVD Market at a glance
02 | STRATEGIC OVERVIEW In Vitro Diagnostic Market IVD Market at a glance The In Vitro Diagnostics (IVD) market remains one of the most dynamic and resilient segments within global healthcare. Following significant expansion during the COVID-19 pandemic, the global IVD market is now undergoing a per
Slide 4: 5 Macro Trends in Healthcare reshaping Diagnostics
02 | STRATEGIC OVERVIEW In Vitro Diagnostic Market | Trends 5 Macro Trends Demographic shift Aging populations & chronic disease burden in Healthcare Consolidation in the Core Labs reshaping High-throughput automation & workflow integration Diagnostics Decentralization Lab to Point-Of-Care migration
Slide 5: Macro Trends: demographic shift, consolidation, decentralization
02 | STRATEGIC OVERVIEW In Vitro Diagnostic Market | Trends 5 Macro Trends in Healthcare reshaping Diagnostics Demographic shift Consolidation in the Core Labs Aging populations & chronic disease burden High-throughput automation Decentralization & workflow integration 1 in 6 people globally over 60
Slide 6: Macro Trends: value-based care and precision medicine
02 | STRATEGIC OVERVIEW In Vitro Diagnostic Market | Trends 5 Macro Trends in Healthcare reshaping Diagnostics Value-Based Care Precision Medicine Regional Dynamics and Complementary United States Diagnostics (CDx) Healthcare spending PAMA recalibration reduced Medicare rates 10- pressure & Value-Ba
Slide 7: Diasorin is well positioned to address key sector trends
02 | STRATEGIC OVERVIEW In Vitro Diagnostic Market | Trends Diasorin is well positioned to address key sector trends DEMOGRAPHIC SHIFT CONSOLIDATION DECENTRALIZATION VALUE-BASED CARE PRECISION MEDICINE AND ❌ Cancer ✔️ NEW ✔️ LIAISON NES ✔️ LIAISON PLEX COMPLEMENTARY ❌ Alzheimer LIAISON XL DIAGNOSTIC
Slide 8: IVD players divided in 2 groups
02 | STRATEGIC OVERVIEW Specialist positioning | Competitors IVD players divided in 2 groups Multi-segment driven by Clinically specialized across technologies Total Lab Automation (TLA) with leadership positions Bacteriology and Immunoassay Microbiology Clinical Chemistry Coagulation LC-Mass-Spec H
Slide 9: Diasorin unique positioning: what it means to be a Specialist in diagnostics
02 | STRATEGIC OVERVIEW Specialist positioning | Diasorin uniqueness Diasorin unique positioning: what does it mean to be a Specialist in diagnostics today Diasorin stands as a unique company EXAMPLES because: H. Pylori Ag, MeMed, C. auris PCR, INFECTIOUS DISEASES It doesn’t play in a unique clinica
Slide 10: Diasorin's Unique Specialist Positioning
02 | STRATEGIC OVERVIEW Specialist positioning | Diasorin’s Unique Specialist Positioning Diasorin’s Unique Specialist Positioning An integrated Specialty Portfolio built around high-value indications, targeted settings, and clinical workflow fit Immunodiagnostics Molecular Diagnostics Licensed Tech
Slide 11: Looking Forward to 2030: what do we commit to deliver
02 | STRATEGIC OVERVIEW Specialist positioning | Diasorin uniqueness Looking Forward to 2030: what do we commit to deliver Immunodiagnostics Molecular Diagnostics Licensed Technologies >20 new specialty assays Increasing competitiveness of New contracts with Diagnostic and LIAISON NES Biopharma part
Slide 12: Slide 12